
K. SHIBATA ET AL.
468
including long-term outcomes and new strategies should
be considered to control disease in which serum CEA
and CA125 are at high levels.
5. Conclusion
Our results suggest that a high level of serum CEA was a
predictive factor for a poor prognosis. Thus, further pro-
spective studies that include many cases are needed, and
strategies should be considered to control disease in this
group of patients.
REFERENCES
[1] M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Can-
cer Statistics,” CA: A Cancer Journal for Clinicians, Vol.
55, No. 2, 2005, pp. 74-108.
doi:10.3322/canjclin.55.2.74
[2] L.-C. Horn, U. Fischer, G. Raptis, K. Bilek and B. Hent-
schel, “Tumor Size Is of Prognostic Value in Surgically
Treated FIGO Stage II Cervical Cancer,” Gynecologic
Oncology, Vol. 107, No. 2, 2007, pp. 310-315.
doi:10.1016/j.ygyno.2007.06.026
[3] C. A. Perez, P. W. Grigsby, K. S. Chao, D. G. Mutch and
M. A. Lockett, “Tumor Size, Irradiation Dose, and Long-
Term Outcome of Carcinoma of Uterine Cervix,” Inter-
national Journal of Radiation Oncology, Biology, Physics,
Vol. 41, No. 2, 1998, pp. 307-317.
doi:10.1016/S0360-3016(98)00067-4
[4] M. Morris, P. J. Eifel, J. Lu, et al., “Pelvic Radiation with
Concurrent Chemotherapy Compared with Pelvic and
Para-Aortic Radiation for High-Risk Cervical Cancer,”
The New England Journal of Medicine, Vol. 340, No. 15,
1999, pp. 1137-1143.
doi:10.1056/NEJM199904153401501
[5] H. M. Keys, B. N. Bundy, F. B. Stehman, et al., “Cis-
platin, Radiation, and Adjuvant Hysterectomy Compared
with Radiation and Adjuvant Hysterectomy for Bulky
Stage IB Cervical Carcinoma,” The New England Journal
of Medicine, Vol. 340, No. 15, 1999, pp. 1154-1161.
doi:10.1056/NEJM199904153401503
[6] P. G. Rose, B. N. Bundy, E. B. Watkins, et al., “Concur-
rent Cisplatin-Based Radiotherapy and Chemotherapy for
Locally Advanced Cervical Cancer,” The New England
Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1144-
1153. doi:10.1056/NEJM199904153401502
[7] W. A. Peters III, P. Y. Liu, R. Barrett, et al ., “Concurrent
Chemotherapy and Pelvic Radiation Therapy Compared
with Pelvic Radiation Therapy Alone as Adjuvant Ther-
apy after Radical Surgery in High-Risk Early-Stage Can-
cer of the Cervix,” Journal of Clinical Oncology, Vol. 18,
No. 8, 2000, pp. 1606-1613.
doi:10.1097/00006254-200008000-00017
[8] K. Shibata, F. Kikkawa, Y. Suzuki, et al., “Usefulness of
Preoperative Chemoradiation in Locally Advanced Cer-
vical Carcinoma,” Gynecologic and Obstetric Investiga-
tion, Vol. 57, No. 2, 2004, pp. 93-99.
doi:10.1159/000075385
[9] C. W. Whitney, W. Sause, B. N. Bundy, et al., “A Ran-
domized Comparison of Fluorouracil Plus Cisplatin ver-
sus Hydroxyurea as an Adjunct to Radiation Therapy in
Stage IIB-IVA Carcinoma of the Cervix with Negative
Para-Aortic Lymph Nodes: A Gynecologic Oncology
Group and Southwest Oncology Group Study,” Journal of
Clinical Oncology, Vol. 17, No. 5, 1999, pp. 1339-1348.
[10] R. Pearcey, M. Brundage, P. Drouin, et al., “Phase III
Trial Comparing Radical Radiotherapy with and without
Cisplatin Chemotherapy in Patients with Advanced Squa-
mous Cell Cancer of the Cervix,” Journal of Clinical
Oncology, Vol. 20, No. 4, 2002, pp. 966-972.
doi:10.1200/JCO.20.4.966
[11] R. S. Lavey, P. Y. Liu, B. E. Greer, et al., “Recombinant
Human Erythropoietin as an Adjunct to Radiation Ther-
apy and Cisplatin for Stage IIB-IVA Carcinoma of the
Cervix: A Southwest Oncology Group Study,” Gyneco-
logic Oncology, Vol. 95, No. 1, 2004, pp. 145-151.
doi:10.1016/j.ygyno.2004.07.009
[12] P. W. Grigsby, M. L. Vest and C. A. Perez, “Recurrent
Carcinoma of the Cervix Exclusively in the Paraaortic
Nodes Following Radiation Therapy,” International Jour-
nal of Radiation Oncology, Biology, Physics, Vol. 28, No.
2, 1994, pp. 451-455. doi:10.1016/0360-3016(94)90070-1
[13] H.-H. Chou, C.-C. Wang, C.-H. Lai, et al., “Isolated
Paraaortic Lymph Node Recurrence after Definitive Irra-
diation for Cervical Carcinoma,” International Journal of
Radiation Oncology, Biology, Physics, Vol. 51, No. 2, 2001,
pp. 442-448. doi:10.1016/S0360-3016(01)01628-5
[14] S. M. Yoon, K. H. Shin, J.-Y. Kim, et al., “The Clinical
Values of Squamous Cell Carcinoma Antigen and Carci-
noembryonic Antigen in Patients with Cervical Cancer
Treated with Concurrent Chemoradiotherapy,” Interna-
tional Journal of Gynecological Cancer, Vol. 17, No. 4,
2007, pp. 872-878.
doi:10.1111/j.1525-1438.2007.00878.x
[15] A. Gadducci, R. Tana, A. Fanucchi and A. R. Genazzani,
“Biochemical Prognostic Factors and Risk of Relapses in
Patients with Cervical Cancer,” Gynecologic Oncology,
Vol. 107, No. 1, 2007, pp. S23-S26.
doi:10.1016/j.ygyno.2007.07.033
[16] M. Hirakawa, Y. Nagai, M. Inamine, et al., “Predictive
Factor of Distant Recurrence in Locally Advanced Squa-
mous Cell Carcinoma of the Cervix Treated with Con-
current Chemoradiotherapy,” Gynecologic Oncology, Vol.
108, No. 1, 2008, pp. 126-129.
doi:10.1016/j.ygyno.2007.08.091
Copyright © 2012 SciRes. SS